<!DOCTYPE html>
<html>
  <head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Problemas no manejo da fibrila√ß√£o atrial</title>
    <link href="/style.css" rel="stylesheet" type="text/css" media="all">
  </head>
  <body>


‚¨ÖÔ∏è <a href="/medruas"> Voltar</a>

<h1>Problemas no manejo da fibrila√ß√£o atrial</h1>

<p>üèó Essa p√°gina ainda est√° inacabada!!!</p>

<p><img src="/assets/img/construcao.gif" alt="Em constru√ß√£o" /></p>

<p>O manejo da fibrila√ß√£o atrial √© um assunto que me gera uma certa angustia porque as diretrizes n√£o s√£o muito claras em alguns pontos e existem situa√ß√µes particulares que n√£o existe nenhuma recomenda√ß√£o forte. Em muitos desses casos a orienta√ß√£o √© individualizar baseado na experi√™ncia e conhecimento do m√©dico  assistente. Entretanto, como prosseguir quando justamente n√£o se tem muita viv√™ncia pr√°tica e repert√≥rio de condu√ß√µes de casos semelhantes?</p>

<p>Claro que se houver especialistas dispon√≠veis √© sempre melhor discutir com eles a melhor conduta, mas nem sempre temos. Ent√£o, s√≥ resta estudar o que dizem as mais variadas literaturas e tentar tra√ßar o pr√≥prio fluxograma, adaptando-o ao longo do tempo. Ao longo desta p√°gina vou listar e detalhar alguns desses problemas espec√≠ficos e discutir sobre o que dizem as literaturas mais renomadas.</p>

<h2 id="anticoagula√ß√£o-na-cardiovers√£o-da-fa-com-dura√ß√£o-menor-que-48-horas">Anticoagula√ß√£o na cardiovers√£o da FA com dura√ß√£o menor que 48 horas</h2>

<p><em>Adendo: 48 horas costuma ser o corte padr√£o mas j√° existem refer√™ncias reduzindo esse intervalo para 24 horas com o objetivo de reduzir ainda mais o risco de tromboembolismo, como a nova diretriz da ESC 2024 (o UpToDate tamb√©m cita que alguns de seus especialistas utilizam o corte de 24 horas e citam o estudo<sup id="fnref:Garg2016" role="doc-noteref"><a href="#fn:Garg2016" class="footnote" rel="footnote">1</a></sup>).</em></p>

<p><strong>√â aceito que pacientes que se apresentam com FA de dura√ß√£o definitivamente menor que 48h podem ser cardiovertidos sem a necessidade de pr√©-anticoagula√ß√£o</strong> por 3-4 semanas, desde que o seu risco tromboemb√≥lico seja baixo (normalmente estimado pelo escore CHA2DS2VASc ‚Äì ou o CHA2DS2VA) e o ritmo sinusal seja atingido dentro dessas 48 horas. Certo, essa recomenda√ß√£o √© at√© um ponto pac√≠fico, <strong>mas e sobre a anticoagula√ß√£o p√≥s-cardiovers√£o por pelo menos 4 semanas? Devemos fazer neses pacientes?</strong></p>

<p>O UpToDate diz:</p>
<blockquote>
  <p>If conversion to SR (either spontaneous or via œ≤–∞r‘ÅiŒøversiŒøn) occurs within 48 hours of the onset of AF, the thromboembolic risk appears to be very low.<sup id="fnref:Pahng2024" role="doc-noteref"><a href="#fn:Pahng2024" class="footnote" rel="footnote">2</a></sup></p>
</blockquote>

<p>Ainda assim, os autores do UpToDate dizem que preferem anticoagular:</p>

<blockquote>
  <p>For most patients in whom œ≤–∞r‘ÅiŒøver—ïi–æn will take place less than 48 hours after the onset of AF, we start a DOAC prior to œ≤–∞r‘ÅiŒøv–µr—ïiŒø’∏ rather than no –∞’∏tiœ≤–æ–∞g’Ωlant. [‚Ä¶] Of note, the approach presented here is in contrast to the historical approach of some cardiologists proceeding to early œ≤–∞r‘ÅiŒøver—ïi–æ’∏ without –∞’∏tiœ≤Œø–∞g’Ωl–∞tion if the duration was less than 24 hours. We generally wait at least two to four hours after the first dose of a DOAC to cardiovert.<sup id="fnref:Pahng2024:1" role="doc-noteref"><a href="#fn:Pahng2024" class="footnote" rel="footnote">2</a></sup></p>
</blockquote>

<blockquote>
  <p>No randomized trial has evaluated –∞’∏tiœ≤Œø–∞gul–∞tion compared with no –∞’∏tiœ≤Œø–∞g’Ωlatio’∏ in AF patients undergoing œ≤–∞r‘ÅiŒøv–µr—ïiŒø’∏ with a definite duration of ŒëF &lt;48 hours. Observational data suggest that the risk of str–æk–µ/thrŒømb–æ–µmboli—ïm is very low (0‚Äâ to‚Äâ0.2 percent) in patients with a definite ŒëF duration of &lt;12 hours and a very low stroke risk (CHA2DS2-VASc 0 in men, 1 in women), in whom the benefit of four-week –∞’∏tiœ≤Œø–∞gul–∞ti–æn after œ≤–∞r‘ÅiŒøv–µr—ïio’∏ is undefined. The 2020 European Society of Cardiology guidelines for the diagnosis and management of ŒëF suggest that prescription of –∞’∏tiœ≤Œøag’Ωl–∞’∏ts can be optional, based on an individualized approach.<sup id="fnref:Pahng2024:2" role="doc-noteref"><a href="#fn:Pahng2024" class="footnote" rel="footnote">2</a></sup></p>
</blockquote>

<blockquote>
  <p>With regard to the question as to whether to anticoagulate these patients or not, there are no studies comparing hep–∞rin with no h–µpari’∏ in patients with AF of less than 48 hours duration. However, data regarding the rate of clinical thromboembolization after œ≤–∞r‘ÅiŒøv–µrsio’∏ in patients with ŒëF of less than 48 hours duration have raised a concern about the safety of œ≤–∞r‘ÅiŒøver—ïi–æn without –∞’∏tiœ≤Œø–∞g’Ωl–∞ti–æ’∏ in this population. In an observational study of 2481 such individuals (5116 successful cardioversions) who were not treated with peri- or postprocedural –∞’∏tiœ≤Œøagulant, definite thromboembolic events occurred in 38 (0.7 percent) within 30 days (median of two days); of these, 31 were strokes [23]. Four additional patients suffered a transient ischemic attack. Age greater than 60 years, female sex, heart failure, and diabetes were the strongest predictors of embolization, with nearly 10 percent of those with both heart failure and diabetes experiencing a —ïtr–æke. The risk of —ïtr–æke in those without heart failure and age less than 60 years was 0.2 percent. An observational study of 16,274 patients undergoing electrical œ≤–∞r‘ÅiŒøv–µr—ïi–æ’∏ with and without oral –∞’∏tiœ≤–æ–∞g’Ωl–∞nt therapy also demonstrated that the absence of postcardioversion –∞’∏tiœ≤Œø–∞g’Ωlation was associated with a high risk of thrŒømbŒøembŒølism, regardless of CHA2DS2-VASc scores [26]. There was a greater-than-twofold increased risk of thrŒømb–æ–µmbŒølism in those not treated with postcardioversion –∞’∏tiœ≤Œø–∞g’Ωl–∞ti–æn (hazard ratio 2.21; 95% CI 0.79-6.77 and 2.40; 95% CI 1.46-3.95 with CHA2DS2-VASc score 0 to 1 and CHA2DS2-VASc score 2 or more, respectively). The rationale for lack of postcardioversion –∞’∏tiœ≤Œø–∞g’Ωl–∞tion could not be exactly discerned in this trial but was deemed to be multifactorial, including presumed short-duration AF, perceived low thromboembolic risk, and lack of guideline adherence.<sup id="fnref:Pahng2024:3" role="doc-noteref"><a href="#fn:Pahng2024" class="footnote" rel="footnote">2</a></sup></p>
</blockquote>

<blockquote>
  <p>Though of unproven in efficacy, some of our contributors recommend –∞’∏tiœ≤Œø–∞g’Ωl–∞tio’∏ for four weeks after reversion to SR (either spontaneous or intended) for patients with AF of less than 48 hours duration, even for those with a low CHA2DS2-VASc score. The rationale for this approach is a concern regarding the high likelihood of ŒëF recurrence in the first month after reversion to SR, as well as transient postcardioversion atrial stunning in the immediate pericardioversion period. This decision may be modified in patients at very high bleeding risk.<sup id="fnref:Pahng2024:4" role="doc-noteref"><a href="#fn:Pahng2024" class="footnote" rel="footnote">2</a></sup></p>
</blockquote>

<p>E em seguida diz:</p>

<blockquote>
  <p>Some of our contributors do not anticoagulate patients with a low CHA2DS2-VASc score (0 in men or 1 in women) after restoration of SR if ŒëF was less than 48 hours duration.</p>
</blockquote>

<p>Ou seja, na pr√°tica cada cardiologista tem sua conduta individualizada. √â algo dificil de determinar porque o risco existe e a decis√£o de anticoagular depende da percep√ß√£o de cada m√©dico de o quanto esse risco (um valor num√©rico) √© aceit√°vel ou n√£o. Para alguns um risco de 0,2% de fazer um AVC/AIT pode ser baixo e para outros pode ser alto, considerando a grande morbidade num paciente jovem e previamente h√≠gido.</p>

<p>O que diz a nova diretriz de FA da ESC de 2024:</p>

<blockquote>
  <p>Any rhythm control procedure has an inherent risk of thrombo¬≠embolism. Patients undergoing cardioversion require at least 3 weeks of therapeutic anticoagulation (adherence to DOACs or INR &gt;2 if VKA) prior to the electrical or pharmacological procedure. In acute set¬≠tings or when early cardioversion is needed, transoesophageal echocar¬≠diography (TOE) can be performed to exclude cardiac thrombus prior to cardioversion. These approaches have been tested in multiple RCTs. In the case of thrombus detection, therapeutic anticoagu¬≠lation should be instituted for a minimum of 4 weeks followed by repeat TOE to ensure thrombus resolution. When the definite duration of AF
is less than 48 hours, cardioversion has typically been considered with¬≠out the need for pre-procedure OAC or TOE for thrombus exclusion. However, the ‚Äòdefinite‚Äô onset of AF is often not known, and observa¬≠tional data suggest that stroke/thromboembolism risk is lowest within a much shorter time period. This task force reached consensus that safety should come first. <strong>Cardioversion is not recommended if AF duration is longer than 24 hours, unless the patient has already received at least 3 weeks of therapeutic anticoagulation or a TOE is performed</strong> to exclude intracardiac thrombus. Most patients should <strong>continue OAC for at least 4 weeks post-cardioversion</strong>. Only for those <strong>without thromboembolic risk</strong> factors and <strong>sinus rhythm restoration within 24h of AF onset</strong> is post-cardioversion OAC optional. In the presence of any thromboembolic risk factors, long-term OAC should be instituted irrespective of the rhythm outcome.<sup id="fnref:Garg2016:1" role="doc-noteref"><a href="#fn:Garg2016" class="footnote" rel="footnote">1</a></sup></p>
</blockquote>

<p>Resumindo a recomenda√ß√£o da ESC:</p>

<ol>
  <li>A anticoatula√ß√£o <strong>pr√©-cardiovers√£o</strong> pode ser dispensada se o in√≠cio foi definitivamente h√° menos de 24 horas.</li>
  <li>A anticoagula√ß√£o <strong>p√≥s-cardiovers√£o</strong> pode ser dispensada se o ritmo sinusal foi atingido com menor de 24 horas de dura√ß√£o fibrila√ß√£o atrial <em>E</em> o paciente possui baixo risco tromboemb√≥lico.</li>
</ol>

<h2 id="refer√™ncias">Refer√™ncias</h2>

<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:Garg2016" role="doc-endnote">
      <p>Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. JACC Clin Electrophysiol. 2016;2(4):487-494. doi:10.1016/j.jacep.2016.01.018¬†<a href="#fnref:Garg2016" class="reversefootnote" role="doc-backlink">&#8617;</a>¬†<a href="#fnref:Garg2016:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a></p>
    </li>
    <li id="fn:Pahng2024" role="doc-endnote">
      <p>Phang R, Manning WJ. Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation. In: UpToDate. Dispon√≠vel em: https://www.uptodate.com/contents/prevention-of-embolization-prior-to-and-after-restoration-of-sinus-rhythm-in-atrial-fibrillation. Acesso em 26 de dezembro de 2024¬†<a href="#fnref:Pahng2024" class="reversefootnote" role="doc-backlink">&#8617;</a>¬†<a href="#fnref:Pahng2024:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a>¬†<a href="#fnref:Pahng2024:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a>¬†<a href="#fnref:Pahng2024:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a>¬†<a href="#fnref:Pahng2024:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a></p>
    </li>
  </ol>
</div>

  </body>
</html>
